Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This will be a prospective observational study of Acthar Gel in Non-Diabetic Hemodialysis
[NDHD] patients receiving dialysis for ≤ 2 years. The project will aimed at providing
proof-of-concept data that 80 U two times [2x] week Acthar for 6 months is a safe and
effective therapy for NDHD. Effectiveness of lower dose 40 U 2X week will also be determined.
Therefore the study will be a repeated measures design (Time x condition) comparison of
improvement in renal function, nutritional status, quality of life and physical performance
resulting from Acthar therapy.